Title:
"No One Has Died from the Coronavirus" - Important revelations shared by Dr Stoian Alexov, President of the Bulgarian Pathology Association
Authors:
Rosemary Frei & Patrick Corbett
Published:
GlobalResearch, 2 July 2020
https://www.globalresearch.ca/no-one-has-died-coronavirus/5717668
From the article:
Dr. Stoian Alexov called the World Health Organization (WHO) a “criminal medical organization” for creating worldwide fear and chaos without providing objectively verifiable proof of a pandemic.
Another stunning revelation from Bulgarian Pathology Association (BPA) president Dr. Alexov is that he believes it’s currently “impossible” to create a vaccine against the virus.
He also revealed that European pathologists haven’t identified any antibodies that are specific for SARS-CoV-2.
These stunning statements raise major questions, including about officials’ and scientists’ claims regarding the many vaccines they’re rushing into clinical trials around the world.
They also raise doubt about the veracity of claims of discovery of anti-novel-coronavirus antibodies (which are beginning to be used to treat patients).
Showing posts with label SARS-CoV-2 antibodies. Show all posts
Showing posts with label SARS-CoV-2 antibodies. Show all posts
Sunday, July 5, 2020
Friday, July 3, 2020
Scholarly Article (Science, 2 July 2020) - Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques
Title:
Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques
Author:
Wei Deng, Linlin Bao, Jiangning Liu, Chong Xiao, Jiayi Liu, Jing Xue, Qi Lv, Feifei Qi, Hong Gao, Pin Yu, Yanfeng Xu, Yajin Qu, Fengdi Li, Zhiguang Xiang, Haisheng Yu, Shuran Gong, Mingya Liu, Guanpeng Wang, Shunyi Wang, Zhiqi Song, Ying Liu, Wenjie Zhao, Yunlin Han, Linna Zhao, Xing Liu, Qiang Wei & Chuan Qin
Published:
Science, 2 July 2020
https://science.sciencemag.org/content/early/2020/07/01/science.abc5343.full
Abstract:
Coronavirus disease 2019 (COVID-19), which is caused by infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic. It currently remains unclear whether convalescing patients have a risk of reinfection. We generated a rhesus macaque model of SARS-CoV-2 infection that was characterized by interstitial pneumonia and systemic viral dissemination mainly in the respiratory and gastrointestinal tracts. Rhesus macaques reinfected with the identical SARS-CoV-2 strain during the early recovery phase of the initial SARS-CoV-2 infection did not show detectable viral dissemination, clinical manifestations of viral disease, or histopathological changes. Comparing the humoral and cellular immunity between primary infection and rechallenge revealed notably enhanced neutralizing antibody and immune responses. Our results suggest that primary SARS-CoV-2 exposure protects against subsequent reinfection in rhesus macaques.
Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques
Author:
Wei Deng, Linlin Bao, Jiangning Liu, Chong Xiao, Jiayi Liu, Jing Xue, Qi Lv, Feifei Qi, Hong Gao, Pin Yu, Yanfeng Xu, Yajin Qu, Fengdi Li, Zhiguang Xiang, Haisheng Yu, Shuran Gong, Mingya Liu, Guanpeng Wang, Shunyi Wang, Zhiqi Song, Ying Liu, Wenjie Zhao, Yunlin Han, Linna Zhao, Xing Liu, Qiang Wei & Chuan Qin
Published:
Science, 2 July 2020
https://science.sciencemag.org/content/early/2020/07/01/science.abc5343.full
Abstract:
Coronavirus disease 2019 (COVID-19), which is caused by infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic. It currently remains unclear whether convalescing patients have a risk of reinfection. We generated a rhesus macaque model of SARS-CoV-2 infection that was characterized by interstitial pneumonia and systemic viral dissemination mainly in the respiratory and gastrointestinal tracts. Rhesus macaques reinfected with the identical SARS-CoV-2 strain during the early recovery phase of the initial SARS-CoV-2 infection did not show detectable viral dissemination, clinical manifestations of viral disease, or histopathological changes. Comparing the humoral and cellular immunity between primary infection and rechallenge revealed notably enhanced neutralizing antibody and immune responses. Our results suggest that primary SARS-CoV-2 exposure protects against subsequent reinfection in rhesus macaques.
Thursday, June 4, 2020
bioRxiv, 3 June 2020 - Brief Communication: Magnetic Immuno-Detection of SARS-CoV-2 specific Antibodies
Title:
Brief Communication: Magnetic Immuno-Detection of SARS-CoV-2 specific Antibodies
Authors:
Jan Pietschmann, Nadja Voepel, Holger Spiegel, Hans-Joachim Krause & Florian Schroeper
Published:
bioRxiv, 3 June 2020
[Keep in mind that this article is a preprint and not yet peer-reviewed.]
https://www.biorxiv.org/content/10.1101/2020.06.02.131102v1
Abstract:
"SARS-CoV-2 causes ongoing infections worldwide, and identifying people with immunity is becoming increasingly important. Available point-of-care diagnostic systems as lateral flow assays have high potential for fast and easy on-site antibody testing but are lacking specificity, sensitivity or possibility for quantitative measurements. Here, a new point-of-care approach for SARS CoV 2 specific antibody detection in human serum based on magnetic immuno-detection is described and compared to standard ELISA. For magnetic immuno-detection, immunofiltration columns were coated with a SARS-CoV-2 spike protein peptide. SARS CoV 2 peptide reactive antibodies, spiked at different concentrations into PBS and human serum, were rinsed through immunofiltration columns. Specific antibodies were retained within the IFC and labelled with an isotype specific biotinylated antibody. Streptavidin-functionalized magnetic nanoparticles were applied to label the secondary antibodies. Enriched magnetic nanoparticles were then detected by means of frequency magnetic mixing detection technology, using a portable magnetic read-out device. Measuring signals corresponded to the amount of SARS CoV 2 specific antibodies in the sample. Our preliminary magnetic immuno-detection setup resulted in a higher sensitivity and broader detection range and was four times faster than ELISA. Further optimizations could reduce assay times to that of a typical lateral flow assay, enabling a fast and easy approach, well suited for point-of-care measurements without expensive lab equipment."
Brief Communication: Magnetic Immuno-Detection of SARS-CoV-2 specific Antibodies
Authors:
Jan Pietschmann, Nadja Voepel, Holger Spiegel, Hans-Joachim Krause & Florian Schroeper
Published:
bioRxiv, 3 June 2020
[Keep in mind that this article is a preprint and not yet peer-reviewed.]
https://www.biorxiv.org/content/10.1101/2020.06.02.131102v1
Abstract:
"SARS-CoV-2 causes ongoing infections worldwide, and identifying people with immunity is becoming increasingly important. Available point-of-care diagnostic systems as lateral flow assays have high potential for fast and easy on-site antibody testing but are lacking specificity, sensitivity or possibility for quantitative measurements. Here, a new point-of-care approach for SARS CoV 2 specific antibody detection in human serum based on magnetic immuno-detection is described and compared to standard ELISA. For magnetic immuno-detection, immunofiltration columns were coated with a SARS-CoV-2 spike protein peptide. SARS CoV 2 peptide reactive antibodies, spiked at different concentrations into PBS and human serum, were rinsed through immunofiltration columns. Specific antibodies were retained within the IFC and labelled with an isotype specific biotinylated antibody. Streptavidin-functionalized magnetic nanoparticles were applied to label the secondary antibodies. Enriched magnetic nanoparticles were then detected by means of frequency magnetic mixing detection technology, using a portable magnetic read-out device. Measuring signals corresponded to the amount of SARS CoV 2 specific antibodies in the sample. Our preliminary magnetic immuno-detection setup resulted in a higher sensitivity and broader detection range and was four times faster than ELISA. Further optimizations could reduce assay times to that of a typical lateral flow assay, enabling a fast and easy approach, well suited for point-of-care measurements without expensive lab equipment."
Wednesday, May 13, 2020
Scholarly Article (bioRxiv, 12 May 2020) - Antiviral options against SARS-CoV-2 infection
Title:
Antiviral options against SARS-CoV-2 infection
Authors:
Aleksandr Ianevski, Rouan Yao, Mona H. Fenstad, Svetlana Biza, Eva Zusinaite, Hilde Lysvand, Kirsti Loeseth, Veslemoy M. Lamndsem, Janne F. Malmring, Valentyn Oksenych, Sten E Erlandsen, Per Arne Aas, Lars Hagen, Caroline H. Pettersen, Jan Egil Afset, Svein Arne Nordbo, Magnar Bjoras, Denis E Kainov
Published:
bioRxiv, 12 May 2020
https://www.biorxiv.org/content/10.1101/2020.05.12.091165v1
[This article is a preprint. It has not been peer-reviewed.]
From the abstract:
"As of May 2020, the number of people infected with SARS-CoV-2 continues to skyrocket, with more than 4,3 million cases worldwide. Both the World Health Organization (WHO) and United Nations (UN) has highlighted the need for better control of SARS-CoV-2 infections. Developing novel virus-specific vaccines, monoclonal antibodies and antiviral drugs against SARS-CoV-2 can be time-consuming and costly. Convalescent plasma and safe-in-man broad-spectrum antivirals (BSAAs) are readily available treatment options. Here we developed a neutralization assay using SARS-CoV-2 virus and monkey Vero-E6 cells. We identified most potent sera from recovered patients for treatment of SARS-CoV-2-infected patients."
Antiviral options against SARS-CoV-2 infection
Authors:
Aleksandr Ianevski, Rouan Yao, Mona H. Fenstad, Svetlana Biza, Eva Zusinaite, Hilde Lysvand, Kirsti Loeseth, Veslemoy M. Lamndsem, Janne F. Malmring, Valentyn Oksenych, Sten E Erlandsen, Per Arne Aas, Lars Hagen, Caroline H. Pettersen, Jan Egil Afset, Svein Arne Nordbo, Magnar Bjoras, Denis E Kainov
Published:
bioRxiv, 12 May 2020
https://www.biorxiv.org/content/10.1101/2020.05.12.091165v1
[This article is a preprint. It has not been peer-reviewed.]
From the abstract:
"As of May 2020, the number of people infected with SARS-CoV-2 continues to skyrocket, with more than 4,3 million cases worldwide. Both the World Health Organization (WHO) and United Nations (UN) has highlighted the need for better control of SARS-CoV-2 infections. Developing novel virus-specific vaccines, monoclonal antibodies and antiviral drugs against SARS-CoV-2 can be time-consuming and costly. Convalescent plasma and safe-in-man broad-spectrum antivirals (BSAAs) are readily available treatment options. Here we developed a neutralization assay using SARS-CoV-2 virus and monkey Vero-E6 cells. We identified most potent sera from recovered patients for treatment of SARS-CoV-2-infected patients."
Tuesday, May 5, 2020
International Business Times, 4 May 2020 - Coronavirus Antibody Test With 100% Accuracy Gets FDA Approval, Step Closer To COVID-19 Immunity
Title:
Coronavirus Antibody Test With 100% Accuracy Gets FDA Approval, Step Closer To COVID-19 Immunity
Author:
Arthur Villasanta
Published:
International Business Times, 4 May 2020
Key points:
* The U.S. FDA has granted emergency use approval to an antibody test with 100% accuracy developed by Roche
* The test is called Elecsys Anti-SARS-CoV-2
* It uses IV blood draws and not finger-prick assays
To read thia article:
https://www.ibtimes.com/coronavirus-antibody-test-100-accuracy-gets-fda-approval-step-closer-covid-19-2969643
Coronavirus Antibody Test With 100% Accuracy Gets FDA Approval, Step Closer To COVID-19 Immunity
Author:
Arthur Villasanta
Published:
International Business Times, 4 May 2020
Key points:
* The U.S. FDA has granted emergency use approval to an antibody test with 100% accuracy developed by Roche
* The test is called Elecsys Anti-SARS-CoV-2
* It uses IV blood draws and not finger-prick assays
To read thia article:
https://www.ibtimes.com/coronavirus-antibody-test-100-accuracy-gets-fda-approval-step-closer-covid-19-2969643
Medical Xpress, 5 May 2020 - Recently recovered COVID-19 patients produce varying virus-specific antibodies
Title:
Recently recovered COVID-19 patients produce varying virus-specific antibodies
By:
Cell Press
Published:
Medical Xpress, 5 May 2020
From the article:
"Most newly discharged patients who recently recovered from COVID-19 produce virus-specific antibodies and T cells, suggests a study published on May 3rd in the journal Immunity, but the responses of different patients are not all the same. While the 14 patients examined in the study showed wide-ranging immune responses, results from the 6 of them that were assessed at two weeks after discharge suggest that antibodies were maintained for at least that long."
To read this article:
https://medicalxpress.com/news/2020-05-recovered-covid-patients-varying-virus-specific.html
Recently recovered COVID-19 patients produce varying virus-specific antibodies
By:
Cell Press
Published:
Medical Xpress, 5 May 2020
From the article:
"Most newly discharged patients who recently recovered from COVID-19 produce virus-specific antibodies and T cells, suggests a study published on May 3rd in the journal Immunity, but the responses of different patients are not all the same. While the 14 patients examined in the study showed wide-ranging immune responses, results from the 6 of them that were assessed at two weeks after discharge suggest that antibodies were maintained for at least that long."
To read this article:
https://medicalxpress.com/news/2020-05-recovered-covid-patients-varying-virus-specific.html
Saturday, May 2, 2020
Video (ZDoggMD, 19 April 2020) titled How Fatal Is COVID? The Stanford Antibody Prevalence Study
Title of video:
How Fatal Is COVID? The Stanford Antibody Prevalence Study
Published:
ZDoggMD, 19 April 2020
Available: https://www.youtube.com/watch?v=T-KpR2NdSos&feature=youtu.be
Video is based on the following scholarly article:
COVID-19 Antibody Seroprevalence in Santa Clara County, California
Authors:
Eran Bendavid, Bianca Mulaney, Neeraj Sood, Soleil Shah, Emilia Ling, Rebecca Bromley-Dulfano, Cara Lai, Zoe Weissberg, Rodrigo Saavedra-Walker, James Tedrow, Dona Tversky, Andrew Bogan, Thomas Kupiec, Daniel Eichner, Ribhav Gupta, John Ioannidis & Jay Bhattacharya
Published:
medRxiv, 14 April 2020
https://www.medrxiv.org/content/10.1101/2020.04.14.20062463v2
This article is a preprint and has not been certified by peer review.
From the abstract:
"Addressing COVID-19 is a pressing health and social concern. To date, many epidemic projections and policies addressing COVID-19 have been designed without seroprevalence data to inform epidemic parameters. We measured the seroprevalence of antibodies to SARS-CoV-2 in a community sample drawn from Santa Clara County. Methods On April 3-4, 2020, we tested county residents for antibodies to SARS-CoV-2 using a lateral flow immunoassay."
How Fatal Is COVID? The Stanford Antibody Prevalence Study
Published:
ZDoggMD, 19 April 2020
Available: https://www.youtube.com/watch?v=T-KpR2NdSos&feature=youtu.be
Video is based on the following scholarly article:
COVID-19 Antibody Seroprevalence in Santa Clara County, California
Authors:
Eran Bendavid, Bianca Mulaney, Neeraj Sood, Soleil Shah, Emilia Ling, Rebecca Bromley-Dulfano, Cara Lai, Zoe Weissberg, Rodrigo Saavedra-Walker, James Tedrow, Dona Tversky, Andrew Bogan, Thomas Kupiec, Daniel Eichner, Ribhav Gupta, John Ioannidis & Jay Bhattacharya
Published:
medRxiv, 14 April 2020
https://www.medrxiv.org/content/10.1101/2020.04.14.20062463v2
This article is a preprint and has not been certified by peer review.
From the abstract:
"Addressing COVID-19 is a pressing health and social concern. To date, many epidemic projections and policies addressing COVID-19 have been designed without seroprevalence data to inform epidemic parameters. We measured the seroprevalence of antibodies to SARS-CoV-2 in a community sample drawn from Santa Clara County. Methods On April 3-4, 2020, we tested county residents for antibodies to SARS-CoV-2 using a lateral flow immunoassay."
Subscribe to:
Posts (Atom)